Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.

Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.

Disclosed are lithium-based formulations and methods of using the same for the prevention and treatment of inflammatory conditions, gout, joint disease, pain and symptoms thereof.

Disclosed are lithium-based formulations and methods of using the same for the prevention and treatment of inflammatory conditions, gout, joint disease, pain and symptoms thereof.

A suspo-emulsion dosage form of anthelmintic drug such as Ivermectin or niclosamide with essential oils was proposed to be used for administration to the nasal cavity and lungs. The suspo-emulsion formulation is to be administered using a suitable medical device. The composition may be used to treat or prevent viral infections such as Covid-19.

A suspo-emulsion dosage form of anthelmintic drug such as Ivermectin or niclosamide with essential oils was proposed to be used for administration to the nasal cavity and lungs. The suspo-emulsion formulation is to be administered using a suitable medical device. The composition may be used to treat or prevent viral infections such as Covid-19.

The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

The present application relates to a pharmaceutical combination, comprising: a) a prophylactically and/or therapeutically effective amount of ascorbic acid or a derivative thereof; and b) a prophylactically and/or therapeutically effective amount of a second therapeutic agent selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, an RXRα inhibitor, Niclosamide, a CK1a inhibitor, and a Frizzled receptor inhibitor.

The present application relates to a pharmaceutical combination, comprising: a) a prophylactically and/or therapeutically effective amount of ascorbic acid or a derivative thereof; and b) a prophylactically and/or therapeutically effective amount of a second therapeutic agent selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, an RXRα inhibitor, Niclosamide, a CK1a inhibitor, and a Frizzled receptor inhibitor.